- 288 Downloads
Trimodality therapy (TMT) for localized muscle-invasive bladder cancer (MIBC) is a substitute for radical cystectomy. TMT consists of chemoradiation and transurethral resection of bladder tumor (TURB). The purpose of bladder preservation is to get advantage of quality of life and prevent morbidities of radical surgery with comparable oncologic outcomes. TMT could be considered not only for patients inappropriate for surgery but also for patients with MIBC who are reluctant to take surgery.
KeywordsBladder preservation Multimodal therapy Muscle-invasive bladder cancer Trimodality therapy Transurethral resection of the bladder Chemoradiation therapy
- 15.Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kubler H, et al. A systemic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36:43–53.CrossRefGoogle Scholar
- 20.Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952–60. http://dx.doi.org/10.1016/j.eururo.2016.12.020.
- 21.Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665–72.CrossRefGoogle Scholar
- 24.Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006;81:9–17.CrossRefGoogle Scholar
- 27.Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, et al. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011;41:1373–9.CrossRefGoogle Scholar
- 31.Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9. https://doi.org/10.1200/jco.2014.57.5548.CrossRefGoogle Scholar
- 34.Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, et al. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol. 2009;32:592–606.CrossRefGoogle Scholar